Mark Jeng
YOU?
Author Swipe
View article: OGCT-07 ICON-RT: A RANDOMIZED PHASE 2 TRIAL OF CONSOLIDATIVE STEREOTACTIC RADIOSURGERY (SRS) VERSUS CONTINUED OSIMERTINIB IN EGFR-MUTANT NSCLC PATIENTS WITH RESIDUAL BRAIN METASTASES FOLLOWING INITIAL TKI RESPONSE
OGCT-07 ICON-RT: A RANDOMIZED PHASE 2 TRIAL OF CONSOLIDATIVE STEREOTACTIC RADIOSURGERY (SRS) VERSUS CONTINUED OSIMERTINIB IN EGFR-MUTANT NSCLC PATIENTS WITH RESIDUAL BRAIN METASTASES FOLLOWING INITIAL TKI RESPONSE Open
BACKGROUND Brain metastases are common in EGFR-mutant NSCLC (EGFR+LC), with >30% of patients experiencing CNS progression despite initial response to first-line Osimertinib. While CNS-penetrant TKIs offer initial intracranial control, t…
View article: Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases
Identifying the genomic landscape of EGFR-mutant lung cancers with central nervous system metastases Open
View article: Supplementary Figure 9 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 9 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 9. Effect of ICI treatment duration on post-discontinuation survival outcomes using a restricted cubic spline model.
View article: Supplementary Figure 3 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 3 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 3. Post-discontinuation survival outcomes according to age, histology, and best overall response.
View article: Supplementary Figure 1 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 1 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 1. Study consort diagram.
View article: Data from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Data from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Purpose:Among patients with advanced non–small cell lung cancer (NSCLC) who discontinue immune checkpoint inhibitors (ICI) because of immune-related adverse events (irAE), post-discontinuation clinical outcomes and factors associated with …
View article: Supplementary Figure 4 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 4 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 4. Post-discontinuation survival outcomes according to best overall response using a modified SD.
View article: Supplementary Tables 1-18 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Tables 1-18 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Tables 1-18
View article: Supplementary Figure 5 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 5 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 5. Post-discontinuation survival outcomes according to type of immune-related adverse events.
View article: Supplementary Figure 7 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 7 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 7. Post-discontinuation survival outcomes according to PD-L1 TPS and TMB.
View article: Supplementary Figure 6 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 6 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 6. Post-discontinuation survival outcomes according to type of therapy used for immune-related adverse events management.
View article: Supplementary Figure 2 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 2 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 2. Timing of ICI discontinuation due to immune-related adverse events.
View article: Supplementary Figure 8 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 8 from Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 8. Post-discontinuation survival outcomes according to ICI treatment duration before discontinuation.
View article: Lack of disease control remains a major barrier to transplant for older patients with AML
Lack of disease control remains a major barrier to transplant for older patients with AML Open
View article: Improved outcomes of octogenarians and nonagenarians with acute myeloid leukemia in the era of novel therapies
Improved outcomes of octogenarians and nonagenarians with acute myeloid leukemia in the era of novel therapies Open
To the Editor: Acute myeloid leukemia (AML) is primarily a disease of the elderly, with the peak age-specific incidence rate occurring in individuals ≥80 years old.1 Because octogenarians and nonagenarians typically have more co-morbiditie…
View article: Enhancer Connectome Nominates Target Genes of Inherited Risk Variants from Inflammatory Skin Disorders
Enhancer Connectome Nominates Target Genes of Inherited Risk Variants from Inflammatory Skin Disorders Open
The vast majority of polymorphisms for human dermatologic diseases fall in noncoding DNA regions, leading to difficulty interpreting their functional significance. Recent work using chromosome conformation capture technology in combination…
View article: Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study
Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study Open
To the Editor: Case reports1Cannon J.G.D. Russell J.S. Kim J. Chang A.L.S. A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery.JAAD Case Rep…
View article: Metabolic reprogramming of human CD8+ memory T cells through loss of SIRT1
Metabolic reprogramming of human CD8+ memory T cells through loss of SIRT1 Open
The expansion of CD8+CD28– T cells, a population of terminally differentiated memory T cells, is one of the most consistent immunological changes in humans during aging. CD8+CD28– T cells are highly cytotoxic, and their frequency is linked…
View article: SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency
SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency Open
View article: Elucidating Molecular Changes in CD8+ T cells During Aging
Elucidating Molecular Changes in CD8+ T cells During Aging Open
One of the consequences of human aging is an overall decline in immune function. A hallmark of this aging process, termed immunosenescence, is the downregulation of co-receptor CD28 from the surface of CD8+ T cells. This population of term…